Gyre Therapeutics, Inc. (GYRE) 10-Year Financial Performance & Capital Metrics

GYRE • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

AboutGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.Show more

Revenue $106M -6.8%
EBITDA $18M +126.8%
Net Income $12M +113.0%
EPS (Diluted) 0.05 +103.5%
Gross Margin 96.33% +0.4%
EBITDA Margin 16.78% +128.8%
Operating Margin 15.28% +125.8%
Net Margin 11.43% +113.9%
ROE 21.51% +110.0%
ROIC 35.12% +109.9%
Debt/Equity 0.02 -44.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 55.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y81.34%

5Y-

3Y143.36%

TTM2.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM107.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM114.6%

ROCE

10Y Avg-57%

5Y Avg-53.38%

3Y Avg-15.81%

Latest15.97%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.75M	399K	1.02M	6K	0	20.95M	7.34M	102.29M	113.45M	105.76M
Revenue Growth %	5.36%	-0.77%	1.55%	-0.99%	-1%	-	-0.65%	12.94%	0.11%	-0.07%
Cost of Goods Sold+	5.96M	10.55M	12.85M	21.47M	146K	9.16M	7.67M	4.79M	4.64M	3.88M
COGS % of Revenue	3.4%	26.45%	12.62%	3579%	-	0.44%	1.05%	0.05%	0.04%	0.04%
Gross Profit+	-4.21M	-10.16M	-11.83M	-21.47M	-146K	11.79M	-332K	97.5M	108.81M	101.87M
Gross Margin %	-2.4%	-25.45%	-11.62%	-3578%	-	0.56%	-0.05%	0.95%	0.96%	0.96%
Gross Profit Growth %	0.16%	-1.41%	-0.16%	-0.81%	0.99%	81.72%	-1.03%	294.67%	0.12%	-0.06%
Operating Expenses+	15.55M	20.82M	22.84M	33.83M	57.13M	69.16M	83.39M	88.29M	176.04M	85.71M
OpEx % of Revenue	8.89%	52.17%	22.44%	5638%	-	3.3%	11.36%	0.86%	1.55%	0.81%
Selling, General & Admin	9.59M	9.26M	9.99M	12.35M	13.27M	16.18M	18.82M	71.61M	75.82M	73.62M
SG&A % of Revenue	5.48%	23.21%	9.82%	2059%	-	0.77%	2.56%	0.7%	0.67%	0.7%
Research & Development	5.96M	11.55M	12.85M	21.47M	43.86M	52.98M	64.57M	16.69M	13.78M	12.02M
R&D % of Revenue	3.4%	28.96%	12.62%	3579%	-	2.53%	8.8%	0.16%	0.12%	0.11%
Other Operating Expenses	0	86K	261K	1.65M	0	0	0	0	86.44M	66K
Operating Income+	-13.8M	-20.42M	-21.82M	-33.82M	-57.28M	-57.37M	-83.73M	9.2M	-67.23M	16.16M
Operating Margin %	-7.89%	-51.17%	-21.44%	-5637%	-	-2.74%	-11.41%	0.09%	-0.59%	0.15%
Operating Income Growth %	0.54%	-0.48%	-0.07%	-0.55%	-0.69%	-0%	-0.46%	1.11%	-8.31%	1.24%
EBITDA+	-13.33M	-20.03M	-21.65M	-33.67M	-57.13M	-57.23M	-83.44M	10.33M	-66.12M	17.75M
EBITDA Margin %	-7.62%	-50.2%	-21.27%	-5612.17%	-	-2.73%	-11.37%	0.1%	-0.58%	0.17%
EBITDA Growth %	0.55%	-0.5%	-0.08%	-0.56%	-0.7%	-0%	-0.46%	1.12%	-7.4%	1.27%
D&A (Non-Cash Add-back)	470K	389K	173K	149K	146K	138K	290K	1.13M	1.11M	1.59M
EBIT	-13.28M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	9.2M	19.21M	16.23M
Net Interest Income+	-960K	0	0	0	2.15M	561K	39K	726K	1.04M	1.55M
Interest Income	518K	3.47M	261K	3.77M	2.15M	561K	39K	726K	1.04M	1.55M
Interest Expense	1.48M	0	0	0	0	0	0	0	0	0
Other Income/Expense	-960K	3.47M	261K	3.77M	2.1M	1.13M	-4.21M	209K	-9.73M	7.05M
Pretax Income+	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	9.41M	-76.97M	23.22M
Pretax Margin %	-8.44%	-42.47%	-21.18%	-5009.17%	-	-2.68%	-11.98%	0.09%	-0.68%	0.22%
Income Tax+	0	0	-173K	0	0	-699K	0	5.1M	8.52M	5.32M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.99%	1%	0.24%	1.21%	0.52%
Net Income+	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-55.54M	-87.93M	2.3M	-92.93M	12.09M
Net Margin %	-8.44%	-42.47%	-21.18%	-5009.17%	-	-2.65%	-11.98%	0.02%	-0.82%	0.11%
Net Income Growth %	0.55%	-0.15%	-0.27%	-0.39%	-0.84%	-0.01%	-0.58%	1.03%	-41.37%	1.13%
Net Income (Continuing)	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-55.54M	-87.93M	4.31M	-85.48M	17.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	29.7M	29.78M	35.08M
EPS (Diluted)+	-49.99	-21.76	-6.30	-2.68	-4.41	-2.93	-2.87	0.03	-1.41	0.05
EPS Growth %	0.51%	0.56%	0.71%	0.57%	-0.65%	0.34%	0.02%	1.01%	-48%	1.04%
EPS (Basic)	-49.99	-21.76	-6.30	-2.68	-4.41	-2.93	-2.87	0.03	-1.41	0.14
Diluted Shares Outstanding	295.27K	778.78K	3.42M	11.21M	12M	19.18M	30.64M	75.69M	65.83M	102.29M
Basic Shares Outstanding	295.27K	778.78K	3.42M	11.21M	12M	19.18M	30.64M	76.74M	65.83M	85.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	68.7M	37.52M	39.11M	123.99M	96.07M	89.51M	51.48M	49.65M	57.22M	64.79M
Cash & Short-Term Investments	32.5M	17.06M	32.44M	120.13M	76.86M	79.35M	46.85M	25.18M	33.51M	26.67M
Cash Only	29.1M	10.26M	14.47M	31.21M	15.37M	30.36M	44.35M	25.18M	33.51M	11.81M
Short-Term Investments	3.4M	6.8M	17.97M	88.91M	61.5M	48.99M	2.5M	0	0	14.86M
Accounts Receivable	492K	31K	24K	0	15M	3.31M	1.82M	15.61M	16.84M	29.15M
Days Sales Outstanding	102.62	28.36	8.61	-	-	57.73	90.43	55.72	54.18	100.62
Inventory	33.79M	19.47M	5.31M	0	0	0	0	6.12M	4.28M	6.34M
Days Inventory Outstanding	2.07K	673.22	150.84	-	-	-	-	466.21	337.05	595.52
Other Current Assets	1.91M	958K	1.33M	3.86M	4.2M	6.84M	2.81M	2.37M	1.04M	1.44M
Total Non-Current Assets+	823K	569K	404K	929K	2.49M	5.34M	4.19M	35.1M	59.32M	60.62M
Property, Plant & Equipment	698K	444K	276K	386K	2.23M	2.27M	3.71M	18.38M	23.78M	25.7M
Fixed Asset Turnover	2.51x	0.90x	3.69x	0.02x	-	9.25x	1.98x	5.57x	4.77x	4.12x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	1.86M	1.7M	1.71M
Long-Term Investments	125K	125K	0	0	0	2.54M	0	7.39M	23.43M	24.57M
Other Non-Current Assets	0	0	128K	543K	257K	528K	472K	7.47M	5.72M	3.03M
Total Assets+	69.52M	38.09M	39.51M	124.92M	98.55M	94.85M	55.66M	84.75M	116.54M	125.41M
Asset Turnover	0.03x	0.01x	0.03x	0.00x	-	0.22x	0.13x	1.21x	0.97x	0.84x
Asset Growth %	-0.38%	-0.45%	0.04%	2.16%	-0.21%	-0.04%	-0.41%	0.52%	0.38%	0.08%
Total Current Liabilities+	37.76M	21.96M	8.74M	4.8M	28.9M	17.8M	14.16M	12.24M	20.05M	19.52M
Accounts Payable	939K	837K	747K	1.25M	4.28M	5.93M	6.42M	122K	355K	108K
Days Payables Outstanding	57.53	28.94	21.22	21.21	10.7K	236.26	305.47	9.29	27.95	10.15
Short-Term Debt	33.74M	19.4M	5.08M	0	483K	663K	1.98M	0	0	0
Deferred Revenue (Current)	438K	283K	212K	0	1000K	1000K	230K	0	79K	156K
Other Current Liabilities	2.64M	1.44M	2.69M	3.55M	7.03M	6.74M	4.07M	4.86M	648K	5.7M
Current Ratio	1.82x	1.71x	4.48x	25.83x	3.32x	5.03x	3.63x	4.06x	2.85x	3.32x
Quick Ratio	0.92x	0.82x	3.87x	25.83x	3.32x	5.03x	3.63x	3.56x	2.64x	2.99x
Cash Conversion Cycle	2.12K	672.63	138.22	-	-	-	-	512.63	363.28	685.99
Total Non-Current Liabilities+	340K	54K	0	174K	1.32M	981K	408K	294K	82.54M	7.49M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.32M	981K	408K	121K	199K	885K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	48K	7K	0	174K	0	0	0	173K	82.13M	5.67M
Total Liabilities	38.1M	22.02M	8.74M	4.97M	30.22M	18.78M	14.57M	12.54M	102.59M	27M
Total Debt+	33.74M	19.4M	5.08M	0	1.8M	1.64M	2.38M	613K	409K	1.6M
Net Debt	4.65M	9.14M	-9.39M	-31.21M	-13.57M	-28.72M	-41.96M	-24.56M	-33.1M	-10.21M
Debt / Equity	1.07x	1.21x	0.17x	-	0.03x	0.02x	0.06x	0.01x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	0.06x	-	0.09x
Net Debt / EBITDA	-	-	-	-	-	-	-	-2.38x	-	-0.58x
Interest Coverage	-9.34x	-	-	-	-	-	-	-	-	-
Total Equity+	31.43M	16.07M	30.77M	119.94M	68.34M	76.07M	41.09M	72.22M	13.95M	98.4M
Equity Growth %	-0.71%	-0.49%	0.91%	2.9%	-0.43%	0.11%	-0.46%	0.76%	-0.81%	6.05%
Book Value per Share	106.43	20.64	8.99	10.70	5.69	3.97	1.34	0.95	0.21	0.96
Total Shareholders' Equity	31.43M	16.07M	30.77M	119.94M	68.34M	76.07M	41.09M	42.52M	-15.83M	63.32M
Common Stock	11K	1K	6K	12K	12K	22K	31K	64K	77K	86K
Retained Earnings	-131.04M	-147.98M	-173.49M	-203.34M	-258.52M	-314.76M	-402.69M	10.05M	-85.54M	-73.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1K	-1K	0	-4K	34K	5K	0	-392K	1.45M	501K
Minority Interest	0	0	0	0	0	0	0	29.7M	29.78M	35.08M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.12M	-18.47M	-19.94M	-28.55M	-43.61M	-55.05M	-83.75M	10.68M	25.89M	-3.64M
Operating CF Margin %	-10.92%	-46.3%	-19.59%	-4758.83%	-	-2.63%	-11.41%	0.1%	0.23%	-0.03%
Operating CF Growth %	0.45%	0.03%	-0.08%	-0.43%	-0.53%	-0.26%	-0.52%	1.13%	1.43%	-1.14%
Net Income	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	4.31M	-85.48M	17.9M
Depreciation & Amortization	470K	389K	173K	149K	146K	138K	290K	1.13M	1.11M	1.59M
Stock-Based Compensation	326K	635K	863K	2.61M	3.2M	0	3.4M	13.37M	7.28M	831K
Deferred Taxes	-370K	0	0	0	-11.42M	0	-3.89M	-838K	-1.16M	-1M
Other Non-Cash Items	1.11M	-3.39M	18K	116K	11.42M	3.63M	3.89M	503K	96.68M	-7.27M
Working Capital Changes	-6.26M	836K	567K	-1.37M	8.21M	-2.57M	483K	-7.8M	7.46M	-15.69M
Change in Receivables	-79K	461K	7K	0	-15M	11.69M	1.5M	-7.92M	1.3M	-9.29M
Change in Inventory	-1.35M	956K	-479K	0	-490K	0	3.88M	-879K	1.75M	-2.14M
Change in Payables	-4.27M	-102K	-90K	500K	3.03M	1.65M	500K	-112K	192K	-245K
Cash from Investing+	37.36M	-1.31M	-11.25M	-71.32M	27.39M	9.66M	48.19M	-13.81M	-19.76M	-19.88M
Capital Expenditures	-272K	-468K	-23K	-376K	-64K	-267K	-839K	-4.99M	-8.52M	-2.31M
CapEx % of Revenue	0.16%	1.17%	0.02%	62.67%	-	0.01%	0.11%	0.05%	0.08%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-125K	2.56M	-57K	-70.94M	27.46M	0	0	-13K	471K	-412K
Cash from Financing+	9.31M	948K	35.4M	111.33M	327K	60.38M	49.55M	0	2.5M	2.1M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-3.95M	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.89M	0	18.27M	0	0	0	6.7M	0	0	1.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.39M	-18.94M	-19.96M	-28.93M	-43.68M	-55.31M	-84.59M	5.68M	17.31M	-6.77M
FCF Margin %	-11.08%	-47.47%	-19.61%	-4821.5%	-	-2.64%	-11.53%	0.06%	0.15%	-0.06%
FCF Growth %	0.44%	0.02%	-0.05%	-0.45%	-0.51%	-0.27%	-0.53%	1.07%	2.05%	-1.39%
FCF per Share	-65.67	-24.32	-5.83	-2.58	-3.64	-2.88	-2.76	0.08	0.26	-0.07
FCF Conversion (FCF/Net Income)	1.30x	1.09x	0.92x	0.95x	0.79x	0.99x	0.95x	4.64x	-0.28x	-0.30x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	6.35M	8.52M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-21.01%	-71.35%	-92.05%	-39.88%	-58.61%	-76.93%	-150.11%	4.06%	-215.71%	21.51%
Return on Invested Capital (ROIC)	-23.33%	-49.98%	-70.25%	-46.07%	-59.87%	-84.27%	-270.2%	29.51%	-353.79%	35.12%
Gross Margin	-240.46%	-2545.36%	-1161.98%	-357800%	-	56.26%	-4.52%	95.31%	95.91%	96.33%
Net Margin	-843.54%	-4246.87%	-2117.98%	-500916.67%	-	-265.14%	-1198.32%	2.25%	-81.92%	11.43%
Debt / Equity	1.07x	1.21x	0.17x	-	0.03x	0.02x	0.06x	0.01x	0.03x	0.02x
Interest Coverage	-9.34x	-	-	-	-	-	-	-	-	-
FCF Conversion	1.30x	1.09x	0.92x	0.95x	0.79x	0.99x	0.95x	4.64x	-0.28x	-0.30x
Revenue Growth	536.36%	-77.2%	155.14%	-99.41%	-100%	-	-64.97%	1293.98%	10.91%	-6.78%

Revenue by Segment

	2021	2022	2024
Product	-	-	105.8M
Product Growth	-	-	-
Collaboration Revenue	7.34M	794K	-
Collaboration Revenue Growth	-	-89.18%	-

Frequently Asked Questions

Valuation & Price

Gyre Therapeutics, Inc. (GYRE) has a price-to-earnings (P/E) ratio of 154.0x. This suggests investors expect higher future growth.

Growth & Financials

Gyre Therapeutics, Inc. (GYRE) reported $107.3M in revenue for fiscal year 2024. This represents a 10% increase from $97.6M in 2011.

Gyre Therapeutics, Inc. (GYRE) saw revenue decline by 6.8% over the past year.

Yes, Gyre Therapeutics, Inc. (GYRE) is profitable, generating $6.7M in net income for fiscal year 2024 (11.4% net margin).

Dividend & Returns

Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 21.5%. This is excellent, indicating efficient use of shareholder capital.

Gyre Therapeutics, Inc. (GYRE) generated $1.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Gyre Therapeutics, Inc. (GYRE) 10-Year Financial Performance & Capital Metrics

GYRE • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesNASH & Liver Diseases

Revenue $106M -6.8%
EBITDA $18M +126.8%
Net Income $12M +113.0%
EPS (Diluted) 0.05 +103.5%
Gross Margin 96.33% +0.4%
EBITDA Margin 16.78% +128.8%
Operating Margin 15.28% +125.8%
Net Margin 11.43% +113.9%
ROE 21.51% +110.0%
ROIC 35.12% +109.9%
Debt/Equity 0.02 -44.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 55.4% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y81.34%

5Y-

3Y143.36%

TTM2.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM107.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM114.6%

ROCE

10Y Avg-57%

5Y Avg-53.38%

3Y Avg-15.81%

Latest15.97%

Peer Comparison

NASH & Liver Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MAZEMaze Therapeutics, Inc.	1.92B	39.81	511.70		31.18%	-33.24%	3.91%	0.14
GNFTGenfit S.A.	313.52M	6.27	209	134.56%	-14.12%	-31.42%	4.54%	0.90
GYREGyre Therapeutics, Inc.	741.77M	7.70	154	-6.78%	6.2%	4.84%		0.02
TVRDTvardi Therapeutics, Inc.	42.31M	4.51	-0.10	-65.96%	-317.54%	-63.46%
UNCYUnicycive Therapeutics, Inc.	134.75M	6.27	-1.12	-100%		-89.15%		0.10
GLTOGalecto, Inc.	38.32M	23.95	-1.29			-237.68%		0.00
IVAInventiva S.A.	1.17B	6.12	-1.73	-47.37%	-13.75%
AKBAAkebia Therapeutics, Inc.	355.59M	1.34	-4.06	-17.7%	-7.07%	-38.24%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.75M	399K	1.02M	6K	0	20.95M	7.34M	102.29M	113.45M	105.76M
Revenue Growth %	5.36%	-0.77%	1.55%	-0.99%	-1%	-	-0.65%	12.94%	0.11%	-0.07%
Cost of Goods Sold+	5.96M	10.55M	12.85M	21.47M	146K	9.16M	7.67M	4.79M	4.64M	3.88M
COGS % of Revenue	3.4%	26.45%	12.62%	3579%	-	0.44%	1.05%	0.05%	0.04%	0.04%
Gross Profit+	-4.21M	-10.16M	-11.83M	-21.47M	-146K	11.79M	-332K	97.5M	108.81M	101.87M
Gross Margin %	-2.4%	-25.45%	-11.62%	-3578%	-	0.56%	-0.05%	0.95%	0.96%	0.96%
Gross Profit Growth %	0.16%	-1.41%	-0.16%	-0.81%	0.99%	81.72%	-1.03%	294.67%	0.12%	-0.06%
Operating Expenses+	15.55M	20.82M	22.84M	33.83M	57.13M	69.16M	83.39M	88.29M	176.04M	85.71M
OpEx % of Revenue	8.89%	52.17%	22.44%	5638%	-	3.3%	11.36%	0.86%	1.55%	0.81%
Selling, General & Admin	9.59M	9.26M	9.99M	12.35M	13.27M	16.18M	18.82M	71.61M	75.82M	73.62M
SG&A % of Revenue	5.48%	23.21%	9.82%	2059%	-	0.77%	2.56%	0.7%	0.67%	0.7%
Research & Development	5.96M	11.55M	12.85M	21.47M	43.86M	52.98M	64.57M	16.69M	13.78M	12.02M
R&D % of Revenue	3.4%	28.96%	12.62%	3579%	-	2.53%	8.8%	0.16%	0.12%	0.11%
Other Operating Expenses	0	86K	261K	1.65M	0	0	0	0	86.44M	66K
Operating Income+	-13.8M	-20.42M	-21.82M	-33.82M	-57.28M	-57.37M	-83.73M	9.2M	-67.23M	16.16M
Operating Margin %	-7.89%	-51.17%	-21.44%	-5637%	-	-2.74%	-11.41%	0.09%	-0.59%	0.15%
Operating Income Growth %	0.54%	-0.48%	-0.07%	-0.55%	-0.69%	-0%	-0.46%	1.11%	-8.31%	1.24%
EBITDA+	-13.33M	-20.03M	-21.65M	-33.67M	-57.13M	-57.23M	-83.44M	10.33M	-66.12M	17.75M
EBITDA Margin %	-7.62%	-50.2%	-21.27%	-5612.17%	-	-2.73%	-11.37%	0.1%	-0.58%	0.17%
EBITDA Growth %	0.55%	-0.5%	-0.08%	-0.56%	-0.7%	-0%	-0.46%	1.12%	-7.4%	1.27%
D&A (Non-Cash Add-back)	470K	389K	173K	149K	146K	138K	290K	1.13M	1.11M	1.59M
EBIT	-13.28M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	9.2M	19.21M	16.23M
Net Interest Income+	-960K	0	0	0	2.15M	561K	39K	726K	1.04M	1.55M
Interest Income	518K	3.47M	261K	3.77M	2.15M	561K	39K	726K	1.04M	1.55M
Interest Expense	1.48M	0	0	0	0	0	0	0	0	0
Other Income/Expense	-960K	3.47M	261K	3.77M	2.1M	1.13M	-4.21M	209K	-9.73M	7.05M
Pretax Income+	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	9.41M	-76.97M	23.22M
Pretax Margin %	-8.44%	-42.47%	-21.18%	-5009.17%	-	-2.68%	-11.98%	0.09%	-0.68%	0.22%
Income Tax+	0	0	-173K	0	0	-699K	0	5.1M	8.52M	5.32M
Effective Tax Rate %	1%	1%	1%	1%	1%	0.99%	1%	0.24%	1.21%	0.52%
Net Income+	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-55.54M	-87.93M	2.3M	-92.93M	12.09M
Net Margin %	-8.44%	-42.47%	-21.18%	-5009.17%	-	-2.65%	-11.98%	0.02%	-0.82%	0.11%
Net Income Growth %	0.55%	-0.15%	-0.27%	-0.39%	-0.84%	-0.01%	-0.58%	1.03%	-41.37%	1.13%
Net Income (Continuing)	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-55.54M	-87.93M	4.31M	-85.48M	17.9M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	29.7M	29.78M	35.08M
EPS (Diluted)+	-49.99	-21.76	-6.30	-2.68	-4.41	-2.93	-2.87	0.03	-1.41	0.05
EPS Growth %	0.51%	0.56%	0.71%	0.57%	-0.65%	0.34%	0.02%	1.01%	-48%	1.04%
EPS (Basic)	-49.99	-21.76	-6.30	-2.68	-4.41	-2.93	-2.87	0.03	-1.41	0.14
Diluted Shares Outstanding	295.27K	778.78K	3.42M	11.21M	12M	19.18M	30.64M	75.69M	65.83M	102.29M
Basic Shares Outstanding	295.27K	778.78K	3.42M	11.21M	12M	19.18M	30.64M	76.74M	65.83M	85.09M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	68.7M	37.52M	39.11M	123.99M	96.07M	89.51M	51.48M	49.65M	57.22M	64.79M
Cash & Short-Term Investments	32.5M	17.06M	32.44M	120.13M	76.86M	79.35M	46.85M	25.18M	33.51M	26.67M
Cash Only	29.1M	10.26M	14.47M	31.21M	15.37M	30.36M	44.35M	25.18M	33.51M	11.81M
Short-Term Investments	3.4M	6.8M	17.97M	88.91M	61.5M	48.99M	2.5M	0	0	14.86M
Accounts Receivable	492K	31K	24K	0	15M	3.31M	1.82M	15.61M	16.84M	29.15M
Days Sales Outstanding	102.62	28.36	8.61	-	-	57.73	90.43	55.72	54.18	100.62
Inventory	33.79M	19.47M	5.31M	0	0	0	0	6.12M	4.28M	6.34M
Days Inventory Outstanding	2.07K	673.22	150.84	-	-	-	-	466.21	337.05	595.52
Other Current Assets	1.91M	958K	1.33M	3.86M	4.2M	6.84M	2.81M	2.37M	1.04M	1.44M
Total Non-Current Assets+	823K	569K	404K	929K	2.49M	5.34M	4.19M	35.1M	59.32M	60.62M
Property, Plant & Equipment	698K	444K	276K	386K	2.23M	2.27M	3.71M	18.38M	23.78M	25.7M
Fixed Asset Turnover	2.51x	0.90x	3.69x	0.02x	-	9.25x	1.98x	5.57x	4.77x	4.12x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	1.86M	1.7M	1.71M
Long-Term Investments	125K	125K	0	0	0	2.54M	0	7.39M	23.43M	24.57M
Other Non-Current Assets	0	0	128K	543K	257K	528K	472K	7.47M	5.72M	3.03M
Total Assets+	69.52M	38.09M	39.51M	124.92M	98.55M	94.85M	55.66M	84.75M	116.54M	125.41M
Asset Turnover	0.03x	0.01x	0.03x	0.00x	-	0.22x	0.13x	1.21x	0.97x	0.84x
Asset Growth %	-0.38%	-0.45%	0.04%	2.16%	-0.21%	-0.04%	-0.41%	0.52%	0.38%	0.08%
Total Current Liabilities+	37.76M	21.96M	8.74M	4.8M	28.9M	17.8M	14.16M	12.24M	20.05M	19.52M
Accounts Payable	939K	837K	747K	1.25M	4.28M	5.93M	6.42M	122K	355K	108K
Days Payables Outstanding	57.53	28.94	21.22	21.21	10.7K	236.26	305.47	9.29	27.95	10.15
Short-Term Debt	33.74M	19.4M	5.08M	0	483K	663K	1.98M	0	0	0
Deferred Revenue (Current)	438K	283K	212K	0	1000K	1000K	230K	0	79K	156K
Other Current Liabilities	2.64M	1.44M	2.69M	3.55M	7.03M	6.74M	4.07M	4.86M	648K	5.7M
Current Ratio	1.82x	1.71x	4.48x	25.83x	3.32x	5.03x	3.63x	4.06x	2.85x	3.32x
Quick Ratio	0.92x	0.82x	3.87x	25.83x	3.32x	5.03x	3.63x	3.56x	2.64x	2.99x
Cash Conversion Cycle	2.12K	672.63	138.22	-	-	-	-	512.63	363.28	685.99
Total Non-Current Liabilities+	340K	54K	0	174K	1.32M	981K	408K	294K	82.54M	7.49M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.32M	981K	408K	121K	199K	885K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	48K	7K	0	174K	0	0	0	173K	82.13M	5.67M
Total Liabilities	38.1M	22.02M	8.74M	4.97M	30.22M	18.78M	14.57M	12.54M	102.59M	27M
Total Debt+	33.74M	19.4M	5.08M	0	1.8M	1.64M	2.38M	613K	409K	1.6M
Net Debt	4.65M	9.14M	-9.39M	-31.21M	-13.57M	-28.72M	-41.96M	-24.56M	-33.1M	-10.21M
Debt / Equity	1.07x	1.21x	0.17x	-	0.03x	0.02x	0.06x	0.01x	0.03x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	0.06x	-	0.09x
Net Debt / EBITDA	-	-	-	-	-	-	-	-2.38x	-	-0.58x
Interest Coverage	-9.34x	-	-	-	-	-	-	-	-	-
Total Equity+	31.43M	16.07M	30.77M	119.94M	68.34M	76.07M	41.09M	72.22M	13.95M	98.4M
Equity Growth %	-0.71%	-0.49%	0.91%	2.9%	-0.43%	0.11%	-0.46%	0.76%	-0.81%	6.05%
Book Value per Share	106.43	20.64	8.99	10.70	5.69	3.97	1.34	0.95	0.21	0.96
Total Shareholders' Equity	31.43M	16.07M	30.77M	119.94M	68.34M	76.07M	41.09M	42.52M	-15.83M	63.32M
Common Stock	11K	1K	6K	12K	12K	22K	31K	64K	77K	86K
Retained Earnings	-131.04M	-147.98M	-173.49M	-203.34M	-258.52M	-314.76M	-402.69M	10.05M	-85.54M	-73.45M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	1K	-1K	0	-4K	34K	5K	0	-392K	1.45M	501K
Minority Interest	0	0	0	0	0	0	0	29.7M	29.78M	35.08M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-19.12M	-18.47M	-19.94M	-28.55M	-43.61M	-55.05M	-83.75M	10.68M	25.89M	-3.64M
Operating CF Margin %	-10.92%	-46.3%	-19.59%	-4758.83%	-	-2.63%	-11.41%	0.1%	0.23%	-0.03%
Operating CF Growth %	0.45%	0.03%	-0.08%	-0.43%	-0.53%	-0.26%	-0.52%	1.13%	1.43%	-1.14%
Net Income	-14.76M	-16.95M	-21.56M	-30.05M	-55.18M	-56.24M	-87.93M	4.31M	-85.48M	17.9M
Depreciation & Amortization	470K	389K	173K	149K	146K	138K	290K	1.13M	1.11M	1.59M
Stock-Based Compensation	326K	635K	863K	2.61M	3.2M	0	3.4M	13.37M	7.28M	831K
Deferred Taxes	-370K	0	0	0	-11.42M	0	-3.89M	-838K	-1.16M	-1M
Other Non-Cash Items	1.11M	-3.39M	18K	116K	11.42M	3.63M	3.89M	503K	96.68M	-7.27M
Working Capital Changes	-6.26M	836K	567K	-1.37M	8.21M	-2.57M	483K	-7.8M	7.46M	-15.69M
Change in Receivables	-79K	461K	7K	0	-15M	11.69M	1.5M	-7.92M	1.3M	-9.29M
Change in Inventory	-1.35M	956K	-479K	0	-490K	0	3.88M	-879K	1.75M	-2.14M
Change in Payables	-4.27M	-102K	-90K	500K	3.03M	1.65M	500K	-112K	192K	-245K
Cash from Investing+	37.36M	-1.31M	-11.25M	-71.32M	27.39M	9.66M	48.19M	-13.81M	-19.76M	-19.88M
Capital Expenditures	-272K	-468K	-23K	-376K	-64K	-267K	-839K	-4.99M	-8.52M	-2.31M
CapEx % of Revenue	0.16%	1.17%	0.02%	62.67%	-	0.01%	0.11%	0.05%	0.08%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-125K	2.56M	-57K	-70.94M	27.46M	0	0	-13K	471K	-412K
Cash from Financing+	9.31M	948K	35.4M	111.33M	327K	60.38M	49.55M	0	2.5M	2.1M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	-3.95M	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.89M	0	18.27M	0	0	0	6.7M	0	0	1.33M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-19.39M	-18.94M	-19.96M	-28.93M	-43.68M	-55.31M	-84.59M	5.68M	17.31M	-6.77M
FCF Margin %	-11.08%	-47.47%	-19.61%	-4821.5%	-	-2.64%	-11.53%	0.06%	0.15%	-0.06%
FCF Growth %	0.44%	0.02%	-0.05%	-0.45%	-0.51%	-0.27%	-0.53%	1.07%	2.05%	-1.39%
FCF per Share	-65.67	-24.32	-5.83	-2.58	-3.64	-2.88	-2.76	0.08	0.26	-0.07
FCF Conversion (FCF/Net Income)	1.30x	1.09x	0.92x	0.95x	0.79x	0.99x	0.95x	4.64x	-0.28x	-0.30x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	6.35M	8.52M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-21.01%	-71.35%	-92.05%	-39.88%	-58.61%	-76.93%	-150.11%	4.06%	-215.71%	21.51%
Return on Invested Capital (ROIC)	-23.33%	-49.98%	-70.25%	-46.07%	-59.87%	-84.27%	-270.2%	29.51%	-353.79%	35.12%
Gross Margin	-240.46%	-2545.36%	-1161.98%	-357800%	-	56.26%	-4.52%	95.31%	95.91%	96.33%
Net Margin	-843.54%	-4246.87%	-2117.98%	-500916.67%	-	-265.14%	-1198.32%	2.25%	-81.92%	11.43%
Debt / Equity	1.07x	1.21x	0.17x	-	0.03x	0.02x	0.06x	0.01x	0.03x	0.02x
Interest Coverage	-9.34x	-	-	-	-	-	-	-	-	-
FCF Conversion	1.30x	1.09x	0.92x	0.95x	0.79x	0.99x	0.95x	4.64x	-0.28x	-0.30x
Revenue Growth	536.36%	-77.2%	155.14%	-99.41%	-100%	-	-64.97%	1293.98%	10.91%	-6.78%

Revenue by Segment

	2021	2022	2024
Product	-	-	105.8M
Product Growth	-	-	-
Collaboration Revenue	7.34M	794K	-
Collaboration Revenue Growth	-	-89.18%	-

Frequently Asked Questions

Valuation & Price

Gyre Therapeutics, Inc. (GYRE) has a price-to-earnings (P/E) ratio of 154.0x. This suggests investors expect higher future growth.

Growth & Financials

Gyre Therapeutics, Inc. (GYRE) reported $107.3M in revenue for fiscal year 2024. This represents a 10% increase from $97.6M in 2011.

Gyre Therapeutics, Inc. (GYRE) saw revenue decline by 6.8% over the past year.

Yes, Gyre Therapeutics, Inc. (GYRE) is profitable, generating $6.7M in net income for fiscal year 2024 (11.4% net margin).

Dividend & Returns

Gyre Therapeutics, Inc. (GYRE) has a return on equity (ROE) of 21.5%. This is excellent, indicating efficient use of shareholder capital.

Gyre Therapeutics, Inc. (GYRE) generated $1.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.